Delcath’s CHOPIN Trial Hits Primary Endpoint

Delcath Systems, Inc. Reports Promising Phase 2 CHOPIN Trial Results for Liver-Dominant Metastatic Uveal Melanoma Delcath Systems, Inc. (NASDAQ: DCTH), a pioneering interventional oncology company focused on liver-directed therapies for primary and metastatic liver cancers, today announced the results of…








